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ABSTRACT 
 
The revolution in nanotechnology has lead to the development of various dosage forms such as vesicular 
drug delivery and in particular liposomes, niosomes, proniosomes, aquasomes, bilosomes etc. The 
disadvantages exhibited by the liposomes, niosomes can be overcome through introduction of proniosomes 
which are compact liquid crystalline structures and convert to niosomes upon hydration. The investigation 
is focused on development and optimization of Betaxolol proniosomes using three square factorial design 
technique with the aid of design expert 11.0 ® trial version. The optimization technique prefers cholesterol 
and span 60 as independent variables and drug content, vesicular size, and entrapment efficacy as 
dependent variables. The design generated total 13 formulations among which F10 exhibited 98.1% drug 
content and 97.3% of entrapment efficacy. In view of other parameters, F10 exhibits 6.5 pH, 3.8 vesicular 
size and follows diffusion mechanism with anomalous drug transport. Hence, the obtained results specify 
that F10 is optimized and can be opted for commercialization. 
Keywords: Betaxolol; Three square factorial design; Proniosomes; ocular hypertension; open angle 
glaucoma. 
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INTRODUCTION 
Niosomes act as drug reservoirs that enable them to 
release the drug through its bi layers and provides 
sustained drug delivery[1-3]. The drug can be targeted 
to specific areas using minute concentrations through 
encapsulation thereby declining the rate of drug 
clearance. The ideology reduced the side effects of the 
drug molecules and served as a frontier in novel drug 
delivery system. Niosomes exhibit both hydrophilic 
and lipophilic properties which enable them to 
incorporate a variety of drug molecules with varied 
solubility[4-7]. In addition, Niosomes offer various 
advantages such as enhanced oral bioavailability, 
permeability for topical application, and various 
routes of administration. Further, the vesicles act as a 
shield in protecting the inside components of 
niosomes from unfavorable environmental 
conditions. Hence, this exclusive property of 
niosomes enables them to encapsulate labile and 
sensitive drug molecules. Niosomes are found to be 
osmotically active which enhances the stability of 
entrapped drug molecule8-11. The composition of 
niosomes includes cholesterol, surfactant and charge 
inducers among which the non-ionic surfactant are 
explicitly preferred in formulating the niosomes. The 
significance of non-ionic surfactants is to decrease 
the irritation at the site if administration and enhance 
the entrapment efficacy of drug molecules in 
proportional to its alkyl chain length. The present 
investigation incorporates span 60 as surfactant 
possessing elevated HLB value and leads to formation 
of bi layer vesicles. The composition also highlights 
cholesterol, a steroidal metabolite of cell membranes 
for imparting the rigidity and orientation of bi layers 
in niosomes. When cholesterol is incorporated with 
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non-ionic surfactants, it reduces the agglomeration 
and enhances the stability of niosomes. Cholesterol 
also prevents the gel to liquid phase transition of bi 
layers which reduces the drug leakage through 
vesicles and enhances the entrapment efficacy of 
drug molecules[12-15]. Apart from the above, the 
current exploration uses maltodextrin as a carrier 
that play a significant role in deciding the flexibility 
and optimization of formulation. The objective of 
current investigation is to formulate and optimize a 
stable, biocompatible, biodegradable and non-toxic 
niosomal formulation and evaluate its various 
parameters in terms of efficacy and predictability[16-
17].  Therefore, the crucial parameters such as drug 
content, entrapment efficacy, and vesicle size are to 
be optimized which in turn depend on concentrations 
of cholesterol and span 60. In order to fulfill the 
desire criteria, the investigation adopts three square 
factorial design for optimization of cholesterol and 
span 60 at three different levels i.e. low, medium, and 
high using design expert® software trial version and 
the corresponding formulations are analyzed. In 
continuation to the above, niosomes possesses 
enhanced chemical stability and low material cost in 
comparison to other vesicular drug delivery systems 
and proved to be useful for commercial production. 
Hence, the future aspects of niosomes lie in 
encapsulation of various drug molecules that serves 
as a promising carrier in achieving desired 
bioavailability and drug targeting characteristics 
with decreased toxicity and side effects.  
Materials and Methods 
Materials used: Betaxolol, cholesterol and span 60 
are procured from Yarrow chemicals, Mumbai. 
Maltodextrin is procured from Finar chemicals, 
Mumbai. Chloroform and methanol are procured 
from S.D. fine chemicals, Mumbai.  
Formulation of Proniosomes 
The proniosomes are prepared by slurry method in 
which 0.5gm of betaxolol hydrochloride and 
predefined concentrations of cholesterol and span 60 
are dissolved in chloroform and methanol (2:1 ratio). 
The mixture is incorporated with 0.2gm of 
maltodextrin and attached to a rotary flash 
evaporator maintained at 45ºC at 60-70 rpm for 
complete removal of organic solvent and generates a 
free flowing product. The product thus obtained is 
dried for overnight in a desiccator for removal of any 
traces amount of solvent and named as betaxolol 
hydrochloride proniosomes. Further, the detailed 
composition of various formulations carried out in 
the current investigation is mentioned in table 1 for 
reference.  
Construction of Calibration Curve 
The calibration curve for betaxolol hydrochloride is 
constructed by dissolving 100mg of betaxolol 
hydrochloride in 100ml of chloroform (Stock solution 
1). From this nearly 10ml of solution is withdrawn 
and diluted with 100ml with chloroform (Stock 
solution 2). Further, from stock solution 2, the 
required concentrations are developed as per the 
beer’s range i.e. 5-30μg/ml and absorbance is 
recorded at 405nm. The details of concentration and 
its corresponding absorbance are specified in Table 1 
and in Figure 1 for reference. 
Table 1: Calibration curve of Betaxolol hydrochloride 
Concentration 
(μg/ml) 
Absorbance 
0 0 
5 0.169 
10 0.315 
15 0.448 
20 0.585 
25 0.710 
30 0.849 
 
Figure 1: Calibration curve of Betaxolol hydrochloride 
Drug Profile and rationality for the preparation of 
Betaxolol HCl Proniosomes 
Betaxolol Hydrochloride is a cardioselective beta-
adrenergic receptor blocking agent indicated for the 
treatment of ocular hypertension and open angle 
glaucoma. Betaxolol is a BCS class 1 drug possessing 
high solubility and high permeability and gets easily 
available at the targeted site producing the required 
therapeutic effect. However, the enhanced penetrable 
property of the drug molecule may create elevated 
drug concentrations at the targeted site and thereby 
generating a toxic effect. Further, the 
pharmacokinetic parameters reveal that it exhibits 
50% of protein binding and upon oral administration 
it undergoes first pass metabolism which reduces its 
bioavailability to 90%. The elimination half life of 
Betaxolol is 15hours and demand optimized 
formulation that meets the required specifications in 
terms of bioavailability and therapeutic effect. 
Therefore, the present investigation is focused on the 
development of proniosomal formulation that can 
release the drug in a sustained manner meeting the 
predetermined pharmaceutical and biological 
attributes. 
Experimental design and statistical analysis 
The factorial design is employed for optimization of 
betaxolol proniosomes in which the concentrations of 
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cholesterol and span 60 are considered as the 
independent variables and entrapment efficacy, drug 
content are considered as the dependent variables. 
The effect of these variables on the prepared 
formulation is assessed at three different levels i.e. 
low, medium, and high and the possible combinations 
of variables  
 in various formulations is depicted in table 3 for 
reference. Among the generated formulations, and 
the cumulative drug release at various time intervals 
such as 2hrs, 12hrs and 24hrs are considered as 
response variables for which the response surface 
methodology (RSM) is applied using Design expert® 
software trial version 11.0 and the corresponding 
polynomial interactions and quadratic equations are 
developed with the aid of multiple regression 
analysis. Therefore, the regression analysis followed 
the equation Y= β0+ β1A+ β2B+ β3AB+ β4A2+ β5B2+ 
β6A2B + β7AB2 + β8A2B2 in which  β0 signifies the 
intercept, A and B are the coded variables with 
respect to independent variables, and A2B2 indicates 
the interaction between the quadratic terms. In a 
similar fashion, the 2-dimentional counter plots were 
generated using Design expert® software trial 
version 11.0 which are quite useful in understating 
the interactions between independent variables and 
the possible outcomes. 
Table 2: Formulation Chart for Betaxolol hydrochloride Proniosomes 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Betaxolol Hcl (mg) 30 30 30 30 30 30 30 30 30 30 30 30 
Cholesterol (mg) 50 30 40 30 50 30 40 30 40 50 30 40 
Span 60 (mg) 20 30 30 20 30 40 40 40 20 40 20 20 
Maltodextrin (mg) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
Chloroform (ml) 6 6 6 6 6 6 6 6 6 6 6 6 
Methanol (ml) 4 4 4 4 4 4 4 4 4 4 4 4 
Phosphate buffer pH 7.4 (ml) 10 10 10 10 10 10 10 10 10 10 10 10 
Table 3: Summarization of various independent and dependent variables 
Independent Variables Levels Used -1 0 +1 
A: Cholesterol (mg) 30 40 50 
B: Span 60 (mg) 20 30 40 
Dependent Variables R1: Entrapment Efficacy %EE 
 
R3: Drug Content (%) 
Response Variables Y1 % drug release in 2 hours 
Y2 % drug release in 12 hours 
Y3 % drug release in 24 hours 
Y4 50% drug release in (T50%) 
Table 4: Indicating the drug content and entrapment efficacy for various formulations 
Formulation Code Cholesterol (mg) Span60 (ml) Drug Content (%) Entrapment Efficacy (%) 
F1 50 20 95.6 93.1 
F2 30 30 89.3 85.4 
F3 40 30 95.1 89.4 
F4 30 20 89.1 83.6 
F5 50 30 97.3 95.2 
F6 30 40 91.5 87.5 
F7 40 40 94.2 91.5 
F8 30 40 92.1 88.1 
F9 40 20 91.5 87.1 
F10 50 40 98.1 97.3 
F11 30 20 88.4 83.4 
F12 40 20 92.6 87.5 
F13 40 40 93.8 91.8 
Table 5: Comparative In-Vitro drug release studies for various formulations 
Time (hrs) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 
1 12.3 8.1 8.3 6.9 10.4 7.2 9.8 6.7 8.2 14.2 7.9 7.9 10.2 
2 23.6 12.5 17.6 7.9 25.8 13.5 19.4 12.8 16.9 29.3 12.1 17.1 21.5 
4 34.5 26.6 35.2 23.1 36.7 30.5 36.3 29.5 36.2 41.9 25.8 35.8 44.1 
6 48.2 36.5 48.6 30.5 47.5 43.7 50.1 43.2 48.2 57.8 36.2 48.3 58.2 
8 58.1 49.7 59.2 42.8 60.2 56.7 61.8 55.7 60.4 66.5 48.8 59.6 70.8 
12 83.4 63.7 75.8 60.4 84.8 69.8 76.2 69.1 74.8 87.6 62.5 74.2 81.2 
24 91.2 75.8 84.5 72.8 93.5 80.1 87.1 79.8 83.9 95.2 73.1 82.2 89.4 
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Evaluation and characterization of Betaxolol 
hydrochloride Proniosomes 
Morphological and Vesicular size analysis 
The vesicular size is determined by using optical 
microscopy method in which a digital camera is fitted 
which is capable of capturing the photograph of the 
prepared formulation under 100X magnification. The 
procedure involves spreading a thin layer of the film 
on the microscope slide, covered with a cover slip and  
the resultant is placed under the microscope. In 
addition, the formulation image is adjusted as per 
the requirement and the dimensions are recorded 
accordingly.  
Drug Content: The drug content is assessed by 
subjecting the specific quantity of the sample in a 
volumetric flask containing 50ml of phosphate buffer 
pH 7.4. The volumetric flask is subjected for magnetic 
stirring for 24hours and the corresponding samples 
are withdrawn which are diluted as per the beers 
range and the drug content is determined. The 
following formulated is accessed for determining the 
drug content of the prepared formulations: 
% Drug Content =  
Absorbance
Slope
 X (Dilution Factor) X 
1
1000
 
Entrapment Efficacy: The entrapment efficacy is 
assessed through centrifugation method in which the 
predetermined quantity of the formulation is placed 
in the ultra centrifuge and subjected for 
centrifugation at 10,000rpm for 15minutes. From the 
resultant the supernatant liquid is separated, diluted 
according to Beer’s range and the corresponding drug 
entrapment is determined at 405nm using UV 
spectrophotometric method. Further, the 
entrapment efficacy is determined using the 
following equation: 
% Entrapment Efficacy =  
Amount of drug entrapped
Amount of drug added
 X 100 
Determination of pH: The pH of the prepared 
formulation is determined by using digital pH meter 
which was initially calibrated using standard 
phosphate buffer pH 7.4. The electrode is inserted 
into the formulation whose pH is to be determined 
and the reading is recorded at room temperature. The 
procedure is repeated for three times and the average 
pH value is recorded. 
Table 6: Comparative in-vitro -drug release studies for various formulations at 2 hrs, 12 hrs, and 24 hrs 
Formulation Factorial Amount (mg) Rel2 h (%) Rel12 h (%) Rel24 h (%) 
Cholesterol Span 60 
F1 50 20 23.6 83.4 91.2 
F2 30 30 12.5 63.7 75.8 
F3 40 30 17.6 75.8 84.5 
F4 30 20 7.9 60.4 72.8 
F5 50 30 25.8 84.8 93.5 
F6 30 40 13.5 69.8 80.1 
F7 40 40 19.4 76.2 87.1 
F8 30 40 12.8 69.1 79.8 
F9 40 20 16.9 74.8 83.9 
F10 50 40 29.3 87.6 95.2 
F11 30 20 12.1 62.5 73.1 
F12 40 20 17.1 74.2 82.2 
F13 40 40 21.5 81.2 89.4 
Table 7: Comparison of various kinetic parameters for prepared formulations 
Formulation 
Code 
Kinetic Parameters  
Zero Order First Order Higuchi Korsemeyer peppas 
Regression 
Coefficient 
Regression 
Coefficient 
Regression 
Coefficient 
Regression 
Coefficient 
“n” 
Values 
F1 0.828 0.445 0.955 0.968 0.654 
F2 0.856 0.512 0.956 0.966 0.766 
F3 0.800 0.466 0.944 0.942 0.762 
F4 0.884 0.564 0.947 0.949 0.846 
F5 0.828 0.447 0.955 0.947 0.689 
F6 0.814 0.496 0.942 0.946 0.812 
F7 0.825 0.452 0.951 0.949 0.718 
F8 0.820 0.505 0.942 0.946 0.835 
F9 0.794 0.465 0.941 0.937 0.767 
F10 0.785 0.402 0.952 0.949 0.609 
F11 0.846 0.511 0.952 0.963 0.766 
F12 0.785 0.462 0.938 0.933 0.768 
F13 0.738 0.421 0.922 0.916 0.710 
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In-vitro drug release studies: The in-vitro drug 
release studies are performed by using USP type 2 
dissolution apparatus in which the dissolution 
medium containing 900ml of phosphate buffer pH 7.4 
is maintained at 37±0.5ºC with paddle speed of 
50rpm throughout the process. In between 
predetermined aliquots of sample is withdrawn and 
the same is replaced with fresh fluid and the 
cumulative drug release is determined at 405nm 
spectrophotometrically  
Release Kinetics: The mechanism of the drug release 
from the prepared formulation is found out through 
interpretation of in-vitro release data to different 
kinetic models such as Zero order, First order, 
Higuchi, and Korsemeyer-peppas. The basic criteria 
for adaptation of specific value depend on its 
goodness of fit and regression coefficient value. 
RESULTS AND DISCUSSION 
Drug content and entrapment efficacy 
In the current investigation various formulations 
were generated by altering the ratio of cholesterol 
and span 60 and analyzed their effect on entrapment 
efficacy and drug content. The results reveal F10 
contains 98.1% drug content and 97.3% entrapment 
efficacy and considered as optimized. In general, as 
per the theoretical background the drug content and 
the entrapment efficacy enhances proportionally 
with cholesterol concentrations up to a certain extent 
and then declines. This might be due to the fact that 
when incorporated along with surfactants it provides 
rigidity and orientation order through alignment of 
OH groups towards aqueous phase and aliphatic 
chain towards hydrocarbon chain of the surfactant. 
Therefore the rigidity occurs through the 
simultaneous arrangement of steroidal skeleton with 
surfactant molecules thereby restricting the free 
movement of the hydrocarbons. The above 
mentioned theory is favored up to a certain 
concentration levels and the same is generated in 
formulation F10 and any further increase in the 
concentrations of cholesterol beyond 50mg has lead 
to the rapid fall down of the above mentioned 
parameters. Since, the optimized formulation is 
based on enhanced entrapment efficacy and drug 
content, the two are quite superior in F10 when 
compared to the rest of the formulations. Hence, in 
view of the above discussion it can be inferred that 
F10 is quite optimized and meets the required 
criteria. The results in related to drug content and 
entrapment efficacy are depicted in table 4 for 
reference. 
In-vitro drug release study: The drug release 
studies for the prepared formulations are assessed 
for the prepared formulations as per the procedure 
described above and the results are predicted in table 
5 for reference. The results reveal a linear release and 
a maximum drug release of 95.2% for F10. Although 
there are other formulations such as F5 and F1 
possessing 93.5% and 91.2% drug release, they are 
not considered as optimized because they possess 
decreased entrapment efficacy and drug content 
when compared to F10. Further, the theoretical 
background for F5 and F1 to exhibit a decreased drug 
release might be due to altered cholesterol: Span 
ratio. It is believed that as the concentration of 
surfactant is increased, the drug release 
characteristics will increase proportionally and the 
same is observed for generated formulations. 
Further, the presence of penetration enhancer in the 
formulations show a significant effect on the drug 
release characteristics and furthering, the increase in 
cholesterol concentration makes the vesicles much 
rigid and thereby preventing the drug leakage. In 
both F5 and F1 the elevated concentrations of 
cholesterol generates enough rigidity of vesicles, 
while the considerable concentrations of span make 
the vesicles fluffy and enhance the desired 
characteristics. Hence, the optimization of both 
concentrations generated F10 that meet the desired 
criteria. In connection to the above, a comparative 
drug release studies for prepared formulations at 
various time intervals such as 2hrs, 12hrs, and 24hrs 
is studied and the same is predicted in table 6 for 
reference. 
Release Kinetics and Statistical analysis: The 
obtained in-vitro drug release data is subjected for 
various kinetic models such as zero order, first order, 
Higuchi, and Korsemeyer peppas model for 
determining the type of drug release and its kinetic 
profile from the Proniosomes (table 7) (Figure 2-13). 
The results followed a linear relationship and 
generated higher R2 values for zero order in 
comparison to first order kinetics which confirms 
that the formulation follows first order kinetics. 
Further, the Higuchi values range from 0.938 to 0.956 
which confirms that the drug follows diffusion 
mechanism. The Korsemeyer peppas data predicts 
the “n” values from (>0.5 and <1) which specifies 
non-fickian diffusion (anomalous drug transport). 
The generated data is subjected to ANOVA studies 
using design expert 11.0® trial version software and 
the polynomial equations in terms of coded equations 
are generate in which the positive sign indicates that 
there is an increase in the dependent variables on 
simultaneous in the independent variables and vice 
versa. 
 
Figure 2: Zero Order release from F1 to F5 
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Figure 3: Zero Order release from F6 to F10 
 
Figure 4: Zero Order release from F11 to F13 
 
Figure 5: Higuchi model from F1 to F5 
 
Figure 6: Higuchi model from F6 to F10 
 
Figure 7: Higuchi model from F11 to F13 
 
Figure 8: First Order release from F1to F5 
 
Figure 9: First Order release from F6 to F10 
 
Figure 10: First Order release from F11 to F13 
 
Figure 11: Korsemeyer Peppas model from F1to F5 
 
Figure 12: Korsemeyer Peppas model from F6 to F10 
V. Viswanath et al., (2020) Int. J. Res. Pharm. Sci & Tech., 1(3), 89-97 
© Rubatosis Publications | International Journal of Research in Pharmaceutical Sciences and Technology 95  
 
Figure 13: Korsemeyer Peppas model from F11 to F13 
 
 
Figure 14: 2-D Counter Plot for Drug Entrapment 
Efficacy 
 
 
Figure 15: 2-D Counter Plot for Percentage Drug 
Content 
 
 
Figure 16: 2-D Counter Plot for 2hrs Drug Release 
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Figure 17: 2-D Counter Plot for 12hrs Drug Release 
 
 
Figure 18: 2-D Counter Plot for 24hrs Drug Release 
Polynomial Equation in terms of coded variables 
For Entrapment Efficacy: Y = 89.40 +4.90A +2.18B -
0.0250AB +0.9000A2 +0.0750B2 -0.0500A2B -0.1250 
AB2 +0.0500A2B2 
For Drug Content: Y = 95.10 +4.00A +0.9750B -
0.1375AB -1.80A2 -2.07B2 +0.4125A2B -0.7125AB2 
+2.34A2B2 
For 2hrs release Y = 17.60 + 6.65A + 1.72B + 
0.6375AB + 1.55A2 + 1.13B2 + 0.4875A2B + 
0.7875AB2 – 1.26A2B2 
For 12hrs Release Y = 75.80 + 10.55A +2.10B -0.95AB 
– 1.55A2 +0.80B2 +0.95A2B - 5250AB2 +0.4250A2B2 
For 24hrs release Y = 84.50 +8.85A + 2.50B -0.75AB 
+0.15A2 +1.15B2 +0.15A2B -0.4750AB2 -0.9750A2B2 
pH and Vesicle analysis: The pH and the 
corresponding vesicle size of various prepared 
formulations are determined using standard pH 
meter and vesicle analysis through optical 
microscopy technique and the results are predicted 
in table 8 for reference. The results specify the pH 
range from 6.1 to 6.7, and vesicle range from 3.1 to 
3.8 which make sense that the prepared formulations 
possess optimized pH and small unilamellar vesicles. 
At the same time the morphological characteristics of 
the particles specify that they are nearly spherical in 
shape with discrete boundaries. 
Table 8: Comparison of pH and vesicle size for various 
formulations 
Formulation Code pH Vesicle size 
F1 6.4 3.4 
F2 6.5 3.6 
F3 6.2 3.8 
F4 6.3 3.5 
F5 6.5 3.1 
F6 6.7 3.6 
F7 6.1 3.5 
F8 6.5 3.8 
F9 6.3 3.4 
F10 6.5 3.8 
F11 6.2 3.5 
F12 6.1 3.7 
F13 6.5 3.6 
 
CONCLUSION 
Niosomes serve as a promising drug delivery for 
various drug molecules because of their explicit 
properties such as enhanced chemical stability, 
purity, low material cost, capability to incorporate 
variety of molecules. The extreme advantages have 
inspired to formulate and optimize the niosomal 
formulation of betaxolol which is drug of choice in 
open angle glaucoma. The research adopts three 
square factorial design for the optimization of 
independent variables such as cholesterol and span 
60 based on which the dependent variables such as 
drug content, entrapment efficacy, and vesicle size 
are estimated. The design developed total 13 
formulations among which F10 exhibits 98.1% drug 
content and 97.3% of entrapment efficacy which is 
found to be quite optimized and meets the required 
criteria. The other parameters such as release 
kinetics reveal that F10 follows first order kinetics 
with diffusion mechanism. The ANOVA studies and 
polynomial equations in terms of coded variables for 
dependent variables signify that there exist a direct 
proportional relationship between the dependent 
and independent variables. Thus in view of above 
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discussion, it can be conclude that F10 is optimized 
formulation that meets the required criteria.  
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